The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.
Contract development and manufacturing organizations cannot develop or distribute vaccines alone, but through partnerships, their infrastructure can provide the foundation for delivering life-saving tools swiftly and equitably when a new public health crisis emerges.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pfizer lowered its revenue projections for 2023, a change it attributed to declining demand for its Covid-19 vaccine, Comirnaty, and antiviral drug, Paxlovid. Citing this revenue decline, Pfizer is implementing a companywide cost-cutting plan projected to save $3.5 billion.
New York, Florida, Texas and Minnesota terminated Medicaid coverage for some enrollees for “unallowable or potentially unallowable reasons” during the Covid-19 public health emergency, according to a recent Office of Inspector General report.
The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review.
In order to gain trust from communities, healthcare leaders will need more training on effective communication, said Dr. Vin Gupta, a pulmonologist and chief medical officer of Amazon Pharmacy. He made these comments last week during a panel at the AHIP 2023 conference in Portland.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
While the U.S. did very well on the scientific front of Covid-19 with the production of vaccines, it needs to improve on the public health front, said Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases. He made these comments Tuesday at the AHIP 2023 conference in Portland.
Dr. Ala Stanford, founder of the Black Doctors Covid-19 Consortium, provided hundreds of thousands of Covid-19 tests and vaccines to Black and Brown people in Philadelphia's underserved neighborhoods during the pandemic. In her view, her work was impactful because she acted promptly and focused on community-based patient engagement.
Paxlovid, a Pfizer antiviral awarded FDA emergency authorization in 2021 for treating Covid-19, is now approved for treating adults. Results from a pivotal clinical trial showed that Paxlovid led to an 86% reduction in Covid-19-related hospitalization or death from any cause compared to a placebo.
The Covid-19 public health emergency ended May 11, which will affect employer-sponsored insurance in several ways, said Jeff Levin-Scherz, population health leader of Willis Towers Watson. This includes the coverage Covid-19 tests and vaccines.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Out of the $1 billion in Medicare payments to providers for psychotherapy services in the first year of Covid-19, $580 million were improper payments, an audit by the Office of Inspector General found. This includes $348 million for telehealth services.
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
Older adults and immunocompromised people may now get a second Covid-19 booster shot, according to amendments to the FDA authorizations of the mRNA vaccines. Further changes will be discussed at an advisory committee meeting planned for June.
The FDA granted emergency use authorization to an InflaRx antibody drug that treats hospitalized Covid-19 patients. But Pardes Bioscience’s coronavirus journey is ending following the Phase 2 failure of an antiviral that was expected to compete with Pfizer’s Paxlovid.
The Covid-19 pandemic has transformed the way we think of diagnostics in our daily lives. In a recent webinar, BD Vice President for Diagnostics Nikos Pavlidis spoke with a clinician and an epidemiologist where they shared their perspectives on how testing developments have changed the way we track respiratory illnesses.